<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="111299">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01655069</url>
  </required_header>
  <id_info>
    <org_study_id>905-CL-077</org_study_id>
    <secondary_id>2011-002047-10</secondary_id>
    <nct_id>NCT01655069</nct_id>
  </id_info>
  <brief_title>A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076</brief_title>
  <acronym>LEOPARD</acronym>
  <official_title>An Open-Label, Long-Term Extension, Multi-center, Sequential Dose Titration Study to Assess Safety and Efficacy of Solifenacin Succinate Suspension in Pediatric Subjects With Overactive Bladder (OAB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Europe B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 40-week study to investigate how safe and effective solifenacin solution is in
      treating children/adolescents with symptoms of overactive bladder (OAB) who completed study
      905-CL-076. To measure the efficacy of the treatment the patient will complete a 7-day
      patient diary prior to every visit, starting at Visit 9. The patient will attend the study
      clinic on 7 separate occasions. The first visit of this study (905-CL-077) will be combined
      with the last visit of the 4-month study 905-CL-076. At each visit, the patient will be
      required to undertake a number of assessments or examinations to determine whether it is
      safe for him/her to take part or to continue to take part in the study. During the first 3
      visits the dosage of the study drug will be adjusted if needed in order to optimize the most
      effective and safe dose for each patient.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events</measure>
    <time_frame>Week 12 to Week 52 (End of study)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of study 905-CL-076 to end of this study in efficacy measured by mean number of incontinence episodes/24 hours</measure>
    <time_frame>Baseline and Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of study 905-CL-076 to end of this study in efficacy measured by number of dry (incontinence-free) days/7 days</measure>
    <time_frame>Baseline and Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of study 905-CL-076 to end of this study in efficacy measured by mean number of micturitions/24 hours</measure>
    <time_frame>Baseline and Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of study 905-CL-076 to end of this study in efficacy measured by mean number of grade 3 or 4 urgency episodes per 24 hours in adolescents</measure>
    <time_frame>Baseline and Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by recording laboratory tests, vital signs, urinalysis, PVR (post void residual) volume and electrocardiograms (ECGs)</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">148</enrollment>
  <condition>Urinary Bladder, Overactive</condition>
  <arm_group>
    <arm_group_label>Solifenacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solifenacin succinate</intervention_name>
    <description>Oral suspension</description>
    <arm_group_label>Solifenacin</arm_group_label>
    <other_name>YM905</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has met the inclusion criteria of study 905-CL-076 and completed study
             905-CL-076

        Exclusion Criteria:

          -  Subject has failed the exclusion criteria of study 905-CL-076
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Study Manager</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Europe B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site: 1006</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3202</name>
      <address>
        <city>Antwerp</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3209</name>
      <address>
        <city>Antwerp</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3208</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3201</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3203</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3204</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3205</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 5507</name>
      <address>
        <city>Campinas</city>
        <zip>13087-567</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 5506</name>
      <address>
        <city>Curitiba</city>
        <zip>80240-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 1001</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 4503</name>
      <address>
        <city>Aalborg</city>
        <zip>DK-9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 4501</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 4504</name>
      <address>
        <city>Koge</city>
        <zip>4600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 4502</name>
      <address>
        <city>Kolding</city>
        <zip>6000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3810</name>
      <address>
        <city>Belgrade</city>
        <zip>11 000</zip>
        <country>Former Serbia and Montenegro</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3812</name>
      <address>
        <city>Novi Sad</city>
        <zip>21000</zip>
        <country>Former Serbia and Montenegro</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 8203</name>
      <address>
        <city>Daegu</city>
        <zip>705717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 8206</name>
      <address>
        <city>Incheon</city>
        <zip>400-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 8207</name>
      <address>
        <city>Seoul</city>
        <zip>110744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 8202</name>
      <address>
        <city>Seoul</city>
        <zip>156707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 5202</name>
      <address>
        <city>Mexico City</city>
        <zip>4530</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 5205</name>
      <address>
        <city>Mexico City</city>
        <zip>C.P.06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 4701</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 6301</name>
      <address>
        <city>Quezon City</city>
        <zip>1108</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 4805</name>
      <address>
        <city>Gdansk</city>
        <zip>80-803</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 4803</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 4804</name>
      <address>
        <city>Lubin</city>
        <zip>20-093</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 4801</name>
      <address>
        <city>Warsaw</city>
        <zip>04-736</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 2703</name>
      <address>
        <city>Cape Town</city>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 4606</name>
      <address>
        <city>Gothenburg</city>
        <zip>41685</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 4603</name>
      <address>
        <city>Skovde</city>
        <zip>54185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 4602</name>
      <address>
        <city>Stockholm</city>
        <zip>11883</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 4605</name>
      <address>
        <city>Umea</city>
        <zip>90185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 9001</name>
      <address>
        <city>Ankara</city>
        <zip>6100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 9002</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3854</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 4403</name>
      <address>
        <city>Leeds</city>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 4401</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Former Serbia and Montenegro</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Norway</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>Sweden</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
    <country>Germany</country>
    <country>India</country>
    <country>Netherlands</country>
    <country>Russian Federation</country>
  </removed_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002047-10/results</url>
    <description>Link to results on EudraCT</description>
  </link>
  <verification_date>July 2015</verification_date>
  <lastchanged_date>July 23, 2015</lastchanged_date>
  <firstreceived_date>July 30, 2012</firstreceived_date>
  <firstreceived_results_disposition_date>July 23, 2015</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Overactive bladder (OAB)</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Solifenacin succinate suspension</keyword>
  <keyword>Phase 3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Solifenacin Succinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
